- The Food and Drug Administration staff said the once-daily tablet, called mirabegron, worked to reduce frequent urination and the inability to control it, according to documents released online on Tuesday. (msnbc.com)
- WASHINGTON, April 3 (Reuters) - U.S. drugs reviewers said Astellas Pharma Incs treatment for an overactive bladder worked, but raised concerns about liver and heart safety issues. The U.S. (Huffington Post)
- The risks were included in a Food and Drug Administration report released today ahead of an April 5 meeting of FDA advisers on the drug, known as mirabegron. To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg. (Bloomberg)
- The first event on the docket is an Advisory Committee meeting for Astellas Pharmas (ALPMY.PK) Mirabegron. Mirabegron is a once daily beta three receptor intended to treat patients with overactive bladder (OAB). (Seekingalpha.com)
- On Thursday, the FDAs Reproductive Health Drugs Advisory Committee will discuss the benefits and risks of beta-3-adrenoceptor (AR) agonist mirabegron to treat overactive bladder. (MedPage Today)
Tuesday, April 3, 2012
Mirabegron
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment